TOTAL VOLUME:

$97.5b

24H VOL:

$266,367,375

24H TRANSACTIONS:

960,901,819

OPEN INTEREST:

$2,196,061,598

832,481

Markets across

15,126

events

MATCHED EVENTS:

961

PLATFORM COVERAGE:

5

Polymarket:

45%

VS.

Kalshi:

55%

BETA
Cyclosporiasis cases in U.S. by July 31?

Cyclosporiasis cases in U.S. by July 31?

Jul 14, 2026, 9:57 PM EST - Jul 31, 2026, 7:59 PM EST
Total volume:
$18,947
Volume 24h:
$8,092N/A
Liquidity:
$13,524
58%
Open interest:
$4,335N/A
PredictionHero
2000+ 95%
polymarket
1800+ 94%
polymarket
2500+ 93%
polymarket
Jul 15, 02:00 AMJul 15, 06:00 AMJul 15, 11:00 AMJul 15, 04:00 PMJul 15, 09:00 PMJul 16, 02:00 AMJul 16, 08:00 AMJul 16, 01:00 PMJul 16, 06:00…406080100

Time left: 15d:05h:31m

Will there be at least 2000 cyclosporiasis cases in the U.S. by July 31, 2026?

95%chance
Amount

$

$20

$50

$100

$500

You will be redirected to the platform to complete this trade.
Outcome
Trade
Chance %
Price
Spread
Liquidity
Volume
24h
7d
Open Interest
Ends in
Result

Description

This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used. Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.

Polymarket

This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used. Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.

Frequently asked questions

On Polymarket, the U.S. cyclosporiasis outbreak market dashboard displays real-time odds and trading activity for whether confirmed cases will reach a specific threshold by mid-2026. Traders buy and sell shares based on their assessment of outbreak severity, with the market price reflecting the collective prediction of participants. The dashboard shows current odds, historical price movements, and trading volume, allowing you to monitor how market sentiment evolves as new public health data emerges. This dynamic pricing mechanism lets you track both expert and crowd forecasts on disease trajectory in one place.

Prediction market odds often diverge from traditional analyst forecasts because they incorporate real-time trading by informed participants with financial incentive to be accurate. While public health agencies and epidemiologists publish outbreak projections based on surveillance data, this market aggregates dispersed knowledge from traders monitoring case counts, transmission patterns, and policy responses. Markets tend to update faster than formal forecasts when new evidence surfaces. Comparing the two reveals whether the crowd is more or less optimistic than official guidance, offering a complementary lens on outbreak trajectory.

On Polymarket, this market is priced through an automated market maker that converts trader activity into real-time odds. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. When you buy shares predicting a higher case count, you push the price up; selling pushes it down. The current odds reflect the marginal trader's belief about outbreak severity by the deadline. Liquidity and trading volume influence how quickly prices adjust to new information, so periods of high activity often correlate with significant public health announcements or case count updates.

This market resolves around Jul 31, 2026, with the outcome confirmed once verified case counts are available from credible public sources. The specific threshold—whether cases reach the predicted level—will be assessed against official U.S. public health reporting at that time. Until resolution, the market remains open for trading, allowing participants to adjust positions as new epidemiological data becomes available. Final settlement depends on the accuracy of reported case totals as of the deadline.

Weekly case reports from the CDC and state health departments are primary catalysts, as rising or falling numbers directly inform outbreak trajectory. Identification of new contamination sources—such as produce recalls or food distribution patterns—can shift expectations sharply. Policy changes, including enhanced surveillance or public warnings, may influence transmission rates and trader positioning. Seasonal factors and travel patterns also matter; summer months historically see cyclosporiasis clusters. Any major shift in confirmed cases or epidemiological findings will likely trigger repricing as traders reassess the probability of reaching the threshold by July 31.

Follow the signals, not the noise

Get insights on market conviction, notable shifts, and what the data is quietly signaling.

PredictionHero © 2026 · v0.20.0PredictionHero provides aggregated market data and informational signals only. Nothing on this site constitutes financial, legal, or investment advice. Markets are volatile and speculative. Past performance does not guarantee future results. Always do your own research and consult qualified professionals before making decisions involving risk. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.